Clinical Trial Update: Cadonilimab for PD-1/PD-L1 Blockade-refractory, MSI-H/dMMR, Advanced Colorectal Cancer [Phase 1, Phase 2]

View source ↗

Summary

Recruiting a Phase 1/2 study of Cadonilimab, a PD-1/PD-L1 bispecific antibody, for PD-1/PD-L1 blockade-refractory, MSI-H/dMMR advanced colorectal cancer (Stage …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Cadonilimab

Snippet

Sponsor: Sun Yat-sen University | Conditions: Colorectal Cancer Stage IV, Mismatch Repair-deficient (dMMR) | Phase 1, Phase 2 | Status: RECRUITING